Scarica l'app Stockscreener
16.03
2.34%
-0.43
Dopo l'orario di chiusura:
16.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$16.46
Aprire:
$16.57
Volume 24 ore:
3.27M
Relative Volume:
1.23
Capitalizzazione di mercato:
$3.19B
Reddito:
$3.90B
Utile/perdita netta:
$-413.00M
Rapporto P/E:
-7.744
EPS:
-2.07
Flusso di cassa netto:
$365.00M
1 W Prestazione:
+2.52%
1M Prestazione:
+0.47%
6M Prestazione:
-17.69%
1 anno Prestazione:
-39.18%
Intervallo 1D:
$16.01
$16.59
Intervallo di 1 settimana:
$15.62
$16.96
Portata 52W:
$12.16
$27.95
Dentsply Sirona Inc Stock (XRAY) Company Profile
Nome
Dentsply Sirona Inc
Settore
Industria
Telefono
844-546-3722
Indirizzo
13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE, NC
Confronta XRAY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XRAY
Dentsply Sirona Inc
|
16.03 | 3.36B | 3.90B | -413.00M | 365.00M | -2.07 |
|
ISRG
Intuitive Surgical Inc
|
495.86 | 179.91B | 9.15B | 2.61B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
185.45 | 52.33B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
91.86 | 45.61B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
275.22 | 40.08B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
263.52 | 16.33B | 2.90B | 467.20M | 306.90M | 6.37 |
Dentsply Sirona Inc Stock (XRAY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-15 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-13 | Downgrade | Needham | Buy → Hold |
| 2025-02-14 | Iniziato | Wells Fargo | Equal Weight |
| 2025-01-23 | Downgrade | Jefferies | Buy → Hold |
| 2025-01-07 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-12-04 | Iniziato | Mizuho | Neutral |
| 2024-11-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-10-25 | Reiterato | Needham | Buy |
| 2024-08-20 | Reiterato | Needham | Buy |
| 2024-02-26 | Iniziato | Leerink Partners | Outperform |
| 2023-11-16 | Iniziato | Needham | Buy |
| 2023-11-10 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-01-12 | Aggiornamento | William Blair | Underperform → Mkt Perform |
| 2022-08-05 | Downgrade | William Blair | Mkt Perform → Underperform |
| 2022-06-02 | Aggiornamento | UBS | Neutral → Buy |
| 2022-04-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-04-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2022-04-19 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-04-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-01-31 | Iniziato | Morgan Stanley | Overweight |
| 2021-10-01 | Ripresa | Credit Suisse | Outperform |
| 2021-08-09 | Reiterato | H.C. Wainwright | Neutral |
| 2021-08-06 | Reiterato | Barrington Research | Outperform |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2021-03-02 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2021-03-02 | Reiterato | H.C. Wainwright | Neutral |
| 2021-01-05 | Reiterato | H.C. Wainwright | Neutral |
| 2020-12-18 | Downgrade | Stifel | Buy → Hold |
| 2020-11-17 | Downgrade | Barclays | Equal Weight → Underweight |
| 2020-11-09 | Reiterato | H.C. Wainwright | Neutral |
| 2020-10-22 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-08-10 | Reiterato | H.C. Wainwright | Neutral |
| 2020-06-16 | Iniziato | Piper Sandler | Overweight |
| 2020-06-15 | Reiterato | H.C. Wainwright | Neutral |
| 2020-05-27 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-05-11 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2020-04-24 | Reiterato | H.C. Wainwright | Neutral |
| 2020-04-08 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2020-04-07 | Downgrade | Goldman | Buy → Neutral |
| 2020-04-02 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-03-03 | Reiterato | H.C. Wainwright | Neutral |
| 2020-02-19 | Reiterato | Stifel | Buy |
| 2019-12-11 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-08-02 | Aggiornamento | Wellington Shields | Hold → Gradually Accumulate |
| 2019-07-26 | Iniziato | Evercore ISI | In-line |
| 2019-07-09 | Reiterato | H.C. Wainwright | Neutral |
| 2019-05-30 | Iniziato | Wolfe Research | Peer Perform |
Mostra tutto
Dentsply Sirona Inc Borsa (XRAY) Ultime notizie
Is DENTSPLY SIRONA Inc. a good long term investmentConsistent wealth multiplication - PrintWeekIndia
What analysts say about DENTSPLY SIRONA Inc. stockExplosive wealth accumulation - PrintWeekIndia
Does DENTSPLY SIRONA Inc. stock pay reliable dividendsFree Technical Analysis Support - jammulinksnews.com
Dentsply Sirona (XRAY) Stock Outlook: Analyst Maintains Outperform Rating and $21 Price Target - AInvest
Dentsply Sirona names Daniel Scavilla as new CEO, reaffirms 2025 outlook - MSN
G-III, Tecnoglass, MYR Group, Jabil, and Dentsply Sirona Shares Are Soaring, What You Need To Know - TradingView
DENTSPLY SIRONA Inc. Stock Analysis and ForecastUnprecedented market success - Autocar Professional
What drives DENTSPLY SIRONA Inc. stock priceFree Popular Stock Recommendations - Autocar Professional
Forecasting The Future: 4 Analyst Projections For Dentsply Sirona - Nasdaq
Macro Challenges and Soft Demand Muddy Dentsply's Recovery Plan, but Our Positive Outlook Remains - Morningstar
Globus promotes Keith Pfeil to CEO as former exec leaves for Dentsply - MedTech Dive
Here's Why Dentsply International (XRAY) is a Strong Value Stock - Yahoo Finance
Dental Implants and Prosthetics Market is projected to reach US$ - openPR.com
Dentsply Sirona names Daniel Scavilla as new CEO - Dental Tribune US
Dental Equipment Market is projected to reach US$ 12.4 billion - openPR.com
Dental Burs Market Gains Momentum in Aesthetic Dentistry - openPR.com
DENTSPLY SIRONA's Cautious Outlook Amid Leadership Transition and Limited Growth Potential - AInvest
Globus Medical CEO leaves for Dentsply Sirona corner office - MassDevice
Dentsply Sirona (XRAY) Stock Is Up, What You Need To Know - Yahoo Finance
Equinix, Gevo, Dentsply Sirona - TradingView
DENTSPLY SIRONA's Leadership Transition and Strategic Reinvigoration: A Catalyst for Long-Term Value Creation - AInvest
Daniel Scavilla Named CEO of Dentsply Sirona - Dentistry Today
Dentsply Sirona Names New CEO And Beats Expectations - Finimize
Dentsply Sirona Hires Globus CEO Dan Scavilla as Chief Exec - Medical Product Outsourcing
Dentsply Sirona names Daniel Scavilla as new CEO effective August 1 - Investing.com India
Dentsply Sirona Appoints Daniel Scavilla as President and CEO, Effective August 1, 2025 - Quiver Quantitative
Dentsply Sirona appoints new CEO, prelim Q2 revenue beats estimates - TradingView
Dentsply Sirona Appoints Daniel Scavilla as Chief Executive Officer - GlobeNewswire
Former Globus Medical CEO Takes Helm at Dentsply Sirona as Q2 Sales Hit $935M - Stock Titan
Dentsply Sirona: CEO Transition Doesn't Sway Our Favorable Long-Term Outlook - Morningstar
Lobbying Update: $80,000 of DENTSPLY SIRONA INC. lobbying was just disclosed - Quiver Quantitative
Dentsply Sirona Inc Azioni (XRAY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.10%
5.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):